PARIS – Siemens Healthineers AG has unveiled its growth plans for 2025 at its annual general meeting. The Erlangen, Germany-based medical technology giant, valued at nearly $67 billion on the Frankfurt stock exchange, is ramping growth. “We are setting ourselves the objective of annual growth of up to 8% on a like-for-like basis up to 2025, compared with a previous objective of 5%,” said Ralf Thomas, supervisory board chairman, Siemens Healthineers AG. Adjusted earnings per share should, accordingly, rise by 15% a year over that period as part of this strategic plan, compared with a target of at least 10% previously.
PARIS – One year after inception, Lauxera Capital Partners SAS reported final closing of its Lauxera Growth I fund at nearly $300 million, making it the leading European fund devoted to financing health-tech businesses. Lauxera Capital’s objectives involve supporting fast-growing European firms and ramping their international business development.
PARIS – Companion Spine SAS has raised $55 million to help develop its noninvasive diagnostic and interventional implant solutions for the treatment of degenerative disc disease and lumbar spinal stenosis. This series A round was led by Viscogliosi Brothers LLC, a New York-based investment company specializing in financing disruptive technology in spine treatment.
PARIS – Damae Medical SAS has just raised nearly $6 million to develop new technology to detect skin cancer noninvasively without need for a biopsy. This series A round was led by BNP Paribas Développement SA and supported by original investors Kurma Partners SA and professional private equity fund, Paris Saclay Seed Fund.
PARIS – Resilience SAS raised $46 million in a series A round to ramp up European distribution of its mobile application intended for remote monitoring of breast cancer patients, in partnership with the Gustave Roussy Center in Villejuif, France. This funding round was led by two Parisian venture capital funds specializing in digital health – Cathay Innovation SAS and Singular Capital Partners SAS – along with Dutch-based Exor Seeds NV, German-based Picus Capital GmbH and Seaya Capital Gestion, SGEIC, SA, from Spain.
PARIS – An interdisciplinary academic research consortium in Italy has devised and tested nanowires that restore physiological cell-to-cell conductance. This research team, led by the Experimental and Applied Medical Technology Lab (Tecmed Lab) at the Department of Medicine and Surgery at the University of Parma, Italy, has just published the results of multiple local in situ injections of nanowires into left ventricular infarct regions in Nature Communications.
PARIS – Spartha Medical SAS reported an award of $2.7 million in grants with further, undisclosed equity financing from the European Innovation Council (EIC) Fund, a body run by the European Commission established to make direct equity investment in European Union companies. This fund will be used to initiate clinical evaluation of its multifunctional coating technique.
PARIS – Mikajaki SA reported the commercial launch of Eyelib, a robotic ophthalmic diagnostics platform. One year after obtaining CE marking, the Swiss-based med-tech is rolling out a wide-scale launch of its automatic ophthalmology examination system onto the European market.
PARIS – Robocath SAS has concluded an initial clinical study in Europe to demonstrate the safety and efficacy of robotic coronary angioplasty performed using its R-One platform. Sixty-two patients from six European hospitals participated in the R-Evolution clinical study. The study was aimed at assessing the safety and efficacy of the R-One robotic assistance platform.
PARIS – Healshape SAS is preparing a $6.8 million series A round to develop a 3D bioprinted breast implant obtained from the patients' own cells. Supported by Pulsalys SAS, Lyon Saint-Etienne’s technology transfer acceleration company, this startup from Villeurbanne, France, has already benefited from more than a million dollars of French public funding and subsidies.
